adhesion G protein-coupled receptor D1Genealiases: GPR133 · PGR25
Q-omics provides the consensus-scored ADGRD1 profile across patient tissues and cancer cell-line models. ADGRD1 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, ADGRD1 is differentially expressed in 14, with the highest sampling consensus in LUAD. Additionally, ADGRD1 RNA expression shows 19,901 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight MESO, LUAD, and LSCC as cancer lineages where ADGRD1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ADGRD1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ADGRD1 survival associations across molecular data types. ADGRD1 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (10) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ADGRD1 RNA expression–survival associations across cancer types. High ADGRD1 expression shows unfavorable associations in LUSC, LIHC and BLCA, but favorable associations in MESO, LUAD and SKCM. The MESO Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for ADGRD1 RNA expression.
This table summarizes ADGRD1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 5. The strongest signals are observed in LUAD for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for ADGRD1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ADGRD1 shows lower tumor expression in LUAD, KIRC, BLCA, LUSC, KICH and THCA. The LUAD box plot shows higher ADGRD1 RNA expression in normal versus tumor tissue (log2 FC = −2.469, t-test p < 0.001).
This table shows molecular features associated with ADGRD1 in patient tissues and cancer cell lines. In patient samples, ADGRD1 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, ADGRD1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LIVER.
